Rabies

PreclinicalBiologic

Novartis

Rabies is one of 6 biologic programs targeting Shigellosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ShigellosisCompleted

ShigellosisPreclinical

Completed

Competition

Competitive Landscape

5 competitors in Shigellosis

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

—2

Rocephin

CConrado Roberto Hoffmann Filho

Approved

—3

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

2 4

Bacteriophage

AAdaptive Phage Therapeutics, Inc.

Phase 2

1 5

Shigella4v2

LLimmaTech Biologics AG

Phase 2

2 6

Rabies

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Japanese encephalitis1 trial

Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects

Completed· Novartis logo

Novartis·Phase 3·NCT01662440·661 enrolled

Immunogenicity1 trial

Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age

Completed· Novartis logo

Novartis·Phase 3·NCT02177032·885 enrolled

Shigellosis1 trial

Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants

Completed·LLimmaTech Biologics AG·Preclinical·NCT04056117·597 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Rabies. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rabies compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rabies. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Novartis

Rabies

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Japanese encephalitis1 trial

Immunogenicity1 trial

Shigellosis1 trial

References

Drug Info

Quick Facts

Related News